Fortress Biotech (FBIO) Earns News Sentiment Rating of 0.12

News stories about Fortress Biotech (NASDAQ:FBIO) have been trending somewhat positive on Saturday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fortress Biotech earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.0127303108534 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of equities analysts have recently commented on FBIO shares. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Fortress Biotech in a report on Tuesday. Zacks Investment Research upgraded Fortress Biotech from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, ValuEngine cut Fortress Biotech from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $11.00.

Shares of Fortress Biotech (NASDAQ FBIO) traded up $0.07 during trading on Friday, hitting $3.64. The stock had a trading volume of 66,684 shares, compared to its average volume of 78,420. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.69 and a quick ratio of 2.69. Fortress Biotech has a 12-month low of $1.88 and a 12-month high of $5.13.

Fortress Biotech (NASDAQ:FBIO) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.24). The company had revenue of $46.89 million during the quarter, compared to analysts’ expectations of $50.75 million. Fortress Biotech had a negative return on equity of 61.43% and a negative net margin of 65.80%. The company’s revenue for the quarter was up 4709.2% on a year-over-year basis. research analysts forecast that Fortress Biotech will post -1.99 earnings per share for the current year.

In related news, CEO Lindsay A. Md Rosenwald bought 40,000 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was purchased at an average price of $25.00 per share, for a total transaction of $1,000,000.00. Following the acquisition, the chief executive officer now owns 40,000 shares in the company, valued at $1,000,000. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 33.30% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Fortress Biotech (FBIO) Earns News Sentiment Rating of 0.12” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at

About Fortress Biotech

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Insider Buying and Selling by Quarter for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc and related companies with's FREE daily email newsletter.

Leave a Reply